News

When Investors Discovered New Mexico - (Maas Biolab is profiled)
Originally Appeared in a Special Edition of Innovation Magazine (www.innovation-america.org)

August 19, 2014

Increased Individual Ownership Through Share Exchange From Maas Biolab, LLC

March 31, 2014
Helmuth C. von Moltke Steps Down From Maas Biolab, LLC Board

November 8, 2012
Maas Biolab Wins World Cyclosporin Brain Formula Patents

February 9, 2011
Maas Biolab Decreases Holdings in NeuroVive Pharmaceutical

September 21, 2010
Maas Biolab SBIR Enters Phase 2 for Cyclosporin ALS Treatment

December 3, 2008
Maas Biolab Scientists Validate Cyclosporin Human Neuroprotection

November 17, 2008
Maas Biolab Subsidiary NeuroVive Pharmaceutical Raises $1.5 Million in Swedish Public Offering

October 3, 2008
New Mexico Economic Development Department: Maas BiolAB Awarded $2.1 Million SBIR

October 24, 2007
Maas BiolAB Awarded $2.1 Million SBIR for Cyclosporin ALS Treatment

October 11, 2007
Maas BiolAB Presents to Investor Forum

May 7, 2007
TEDCO Awards Four Companies a Total of $200,000 from Ft. Detrick Technology Transfer Initiative

May 2, 2007
Lundaforskning om skydd mot nervgasskador (Lund Research Protects Against Nerve Gas Damage)

(Lund University, Sweden) February 7, 2007
Maas BiolAB Awarded Department of Defense/DTRA Contract

(BUSINESS WIRE) February 5, 2007
Two New Compounds Target Cell Death by Mitochondria

(MDA/ALS Newsmagazine) v12 n2 February 2007


2006 News
2005 News

2004 News

2003 News
2002 News
2001 News
2000 News
1999 News

 

 

© Maas Biolab All rights reserved